Spinogenix's Codabakalner Receives WHO Approval As Nonproprietary Name for SPG601
On July 16, 2026, Spinogenix, Inc., a clinical-stage biopharmaceutical firm, celebrated a major achievement as the World Health Organization (WHO) granted approval for the name 'codabakalner' to be used as the International Nonproprietary Name (INN) for SPG601, the company's investigational therapy. This milestone signifies not only progress in the therapy's development but also highlights Spinogenix's commitment to addressing the challenges of Fragile X syndrome (FXS).
Codabakalner represents a groundbreaking oral therapy that aims to mitigate the cognitive and behavioral challenges associated with FXS, a genetic condition recognized as the leading inherited cause of intellectual disability. It works by modulating large-conductance calcium-activated potassium (BK) channels, which play a crucial role in synaptic function. The ability to effectively target these channels could potentially rectify the synaptic dysfunctions that lead to the various symptoms of FXS, including cognitive and sensory issues.
Dr. Stella Sarraf, the CEO and Founder of Spinogenix, expressed her excitement about this approval: "The recognition of codabakalner marks a significant milestone for our program targeting Fragile X syndrome. As we gear up for the upcoming Phase 2b/3 clinical trial, the establishment of a global non-proprietary name underscores not only the program's maturity but also our dedication to making this innovative therapy available to those suffering from FXS."
The company is currently preparing for the CLARITY Phase 2b/3 trial, which aims to assess the efficacy, safety, and tolerability of codabakalner in male patients diagnosed with FXS. This trial is a pivotal step in evaluating the potential of this first-in-class therapy.
Spinogenix will also take part in the NFXF International Fragile X Conference scheduled to be held in Louisville, Kentucky. Notably, Dr. Craig Erickson, the Chief Medical Advisor for Spinogenix, will present relevant data regarding the new INN and updates on the CLARITY trial.
The importance of having a unique International Nonproprietary Name cannot be overstated. Each INN assigned by the WHO serves a crucial function for healthcare professionals and patients alike by providing a clear and internationally recognized designation for pharmaceutical substances. This helps ensure accurate communication and safe prescribing practices, thus enhancing patient safety.
Codabakalner (SPG601) is an oral treatment currently under investigation for FXS. The therapy's mechanism focuses on correcting abnormalities in synaptic function and neuroexcitability linked with FXS. Research indicates that FXS patients often experience a decrease in BK channel activity, contributing to multiple symptoms of the condition. Codabakalner, being the first clinically evaluated positive modulator of BK channels in FXS patients, has already been shown in a Phase 2a study to have the potential to enhance cognitive, emotional, and sensory experiences by improving BK channel activity.
Spinogenix holds both Orphan Drug and Fast Track designations from the FDA for codabakalner, reflecting its significance in treating FXS. Additionally, it has received orphan medicinal product designation from the European Medicines Agency (EMA). The company is fully engaged in developing innovative solutions aimed at transforming treatments for neurodegenerative, neuropsychiatric, and neurodevelopmental disorders. Spinogenix's goal is to restore depleted synapses and remedy the syndromes associated with FXS.
For those seeking further information about Spinogenix and its pipeline, the company's website offers a comprehensive overview of its ongoing and planned trials, as well as insights into its pioneering therapeutics aimed at meaningful recovery for patients impacted by debilitating conditions such as FXS and others.
Codabakalner represents a groundbreaking oral therapy that aims to mitigate the cognitive and behavioral challenges associated with FXS, a genetic condition recognized as the leading inherited cause of intellectual disability. It works by modulating large-conductance calcium-activated potassium (BK) channels, which play a crucial role in synaptic function. The ability to effectively target these channels could potentially rectify the synaptic dysfunctions that lead to the various symptoms of FXS, including cognitive and sensory issues.
Dr. Stella Sarraf, the CEO and Founder of Spinogenix, expressed her excitement about this approval: "The recognition of codabakalner marks a significant milestone for our program targeting Fragile X syndrome. As we gear up for the upcoming Phase 2b/3 clinical trial, the establishment of a global non-proprietary name underscores not only the program's maturity but also our dedication to making this innovative therapy available to those suffering from FXS."
The company is currently preparing for the CLARITY Phase 2b/3 trial, which aims to assess the efficacy, safety, and tolerability of codabakalner in male patients diagnosed with FXS. This trial is a pivotal step in evaluating the potential of this first-in-class therapy.
Spinogenix will also take part in the NFXF International Fragile X Conference scheduled to be held in Louisville, Kentucky. Notably, Dr. Craig Erickson, the Chief Medical Advisor for Spinogenix, will present relevant data regarding the new INN and updates on the CLARITY trial.
The importance of having a unique International Nonproprietary Name cannot be overstated. Each INN assigned by the WHO serves a crucial function for healthcare professionals and patients alike by providing a clear and internationally recognized designation for pharmaceutical substances. This helps ensure accurate communication and safe prescribing practices, thus enhancing patient safety.
Codabakalner (SPG601) is an oral treatment currently under investigation for FXS. The therapy's mechanism focuses on correcting abnormalities in synaptic function and neuroexcitability linked with FXS. Research indicates that FXS patients often experience a decrease in BK channel activity, contributing to multiple symptoms of the condition. Codabakalner, being the first clinically evaluated positive modulator of BK channels in FXS patients, has already been shown in a Phase 2a study to have the potential to enhance cognitive, emotional, and sensory experiences by improving BK channel activity.
Spinogenix holds both Orphan Drug and Fast Track designations from the FDA for codabakalner, reflecting its significance in treating FXS. Additionally, it has received orphan medicinal product designation from the European Medicines Agency (EMA). The company is fully engaged in developing innovative solutions aimed at transforming treatments for neurodegenerative, neuropsychiatric, and neurodevelopmental disorders. Spinogenix's goal is to restore depleted synapses and remedy the syndromes associated with FXS.
For those seeking further information about Spinogenix and its pipeline, the company's website offers a comprehensive overview of its ongoing and planned trials, as well as insights into its pioneering therapeutics aimed at meaningful recovery for patients impacted by debilitating conditions such as FXS and others.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.